The Nrf2–MafG heterodimer displays unusually tight binding to the ARE, but Sengoku et al. [80] suggested that at high concentrations of Nrf2 (as may be present in some cancers with Keap1 mutations) Nrf2 may be able to activate transcription without the assistance of its Maf partner. The gene discussed is NFE2L2; the disease is cancer.